Literature DB >> 20559915

The translational path includes the FDA's critical path.

Raymond L Woosley1.   

Abstract

Mesh：

Year:  2008        PMID： 20559915     DOI： 10.1007/s12265-008-9043-z

Source DB:  PubMed          Journal:  J Cardiovasc Transl Res        ISSN： 1937-5387            Impact factor:   4.132


× No keyword cloud information.
  5 in total

1.  Drug development and the FDA's Critical Path Initiative.

Authors:  R L Woosley; J Cossman
Journal:  Clin Pharmacol Ther       Date:  2007-01       Impact factor: 6.875

2.  Biomarker qualification pilot process at the US Food and Drug Administration.

Authors:  Federico Goodsaid; Felix Frueh
Journal:  AAPS J       Date:  2007-03-23       Impact factor: 4.009

Review 3.  The FDA critical path initiative and its influence on new drug development.

Authors:  Janet Woodcock; Raymond Woosley
Journal:  Annu Rev Med       Date:  2008       Impact factor: 13.739

4.  Sematech: purpose and performance.

Authors:  D A Irwin; P J Klenow
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-12       Impact factor: 11.205

5.  The Predictive Safety Testing Consortium: A synthesis of the goals, challenges and accomplishments of the Critical Path.

Authors:  Federico M Goodsaid; Felix W Frueh; William Mattes
Journal:  Drug Discov Today Technol       Date:  2007
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.